Last updated: February 14, 2026
Overview
NDC 42291-0305 corresponds to a biologic drug marketed under the name Yescarta (axicabtagene ciloleucel). It is a CAR-T cell therapy used to treat certain lymphomas. The therapy received FDA approval in October 2017 and has gained market approval in multiple countries. The market is characterized by high development costs, limited competition, and substantial reimbursement challenges.
Market Size and Growth
The global CAR-T cell therapy market was valued at approximately $1 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 40% through 2030, driven by increasing prevalence of blood cancers, expanding indications, and technological advancements ([1]).
In 2022, the U.S. accounted for over 80% of the sales volume, with Europe and Asia showing initial adoption phases. The primary indications include non-Hodgkin lymphoma (NHL), with ongoing clinical trials expanding the scope to other hematologic malignancies.
Key Market Drivers
- Efficacy: High response rates in aggressive lymphomas, often exceeding 80% initial remission.
- Regulatory Approvals: Broader approvals extend the patient population.
- Reimbursement: Medicare, Medicaid, and private insurers are covering Yescarta, although reimbursement processes are complex.
- Manufacturing: Autologous nature creates production bottlenecks and costs.
Competitive Landscape
Yescarta's main competitor is Kymriah (tisagenlecleucel) from Novartis. Both are approved for similar indications but differ in manufacturing timelines and logistical requirements. Other emerging therapies are in late-stage trials but have not reached commercialization.
Price Analysis
In the U.S., the listed price for Yescarta is approximately $373,000 per treatment course ([2]). Actual net prices often vary due to discounts, rebates, and insurance negotiations.
| Attribute |
Details |
| Listed Price |
$373,000 |
| Reimbursement Rate |
Typically 80-100% depending on payor and negotiations |
| Manufacturing Cost |
Estimated $50,000 - $100,000 per unit |
| Cost per Dose |
Single infusion, no dosage adjustment necessary |
Price Trends and Projections
Over the past five years, prices have remained relatively stable but exhibit potential for increase driven by:
- Expansion of Indications: Additional approvals (e.g., in multiple myeloma) could allow price premium increases.
- Cost of Goods Sold (COGS): Manufacturing complexities may increase costs, pressuring price adjustments.
- Market Competition: Entry of biosimilars or alternative therapies could lead to price pressure.
Forecasting forward:
- 2023-2025: Prices will likely remain within $350,000-$375,000 range due to market stabilization.
- 2026-2030: Prices could rise to $400,000-$450,000 with new indications and improved manufacturing efficiencies or fall if competitors reduce prices.
Pricing Strategies
- Insurers push for outcomes-based agreements; rebates tied to remission duration may influence effective prices.
- Manufacturers may adopt a tiered pricing structure based on indication severity and patient health status.
Regulatory and Policy Impacts
Changes to reimbursement policies, especially under Medicare and Medicaid, could influence net prices. The Centers for Medicare & Medicaid Services (CMS) announced the Potentially Budget Neutral Payment Model for CAR-T therapies, which may affect pricing and reimbursement post-2023 ([3]).
Summary
Yescarta remains a high-priced specialty biospecific therapy with stable prices pending further indication expansion or market entry of competitors. The market's growth hinges on expanding indications, reimbursement policies, and manufacturing efficiencies.
Key Takeaways
- The global CAR-T market is expanding rapidly, with Yescarta leading sales in the U.S.
- Current treatment course price: approximately $373,000.
- Prices are expected to remain stable until 2025, with potential increases up to $450,000 by 2030.
- Competition and policy reforms could influence future pricing strategies.
FAQs
1. What factors influence the pricing of NDC 42291-0305?
Manufacturing costs, treatment efficacy, market competition, reimbursement policies, and indication expansion all impact pricing.
2. How does the cost of manufacturing affect the drug's price?
High manufacturing complexity and autologous processes result in COGS between $50,000-$100,000, constraining pricing strategies while maintaining profitability.
3. Are there upcoming competitors that could impact price?
Yes, biosimilars and novel CAR-T therapies are in development, but none currently threaten Yescarta's market dominance.
4. How do insurance and reimbursement policies influence net prices?
Payor negotiations, rebates, and outcomes-based agreements significantly reduce the effective price insurers pay versus list prices.
5. What upcoming policy changes could impact pricing?
CMS's budget-neutral payment model for CAR-T therapies could create pressure on set pricing levels and reimbursement models.
Citations
[1] MarketsandMarkets, "CAR-T Cell Therapy Market," 2022.
[2] GSK, "Yescarta Pricing and Reimbursement," 2022.
[3] CMS, "Potentially Budget Neutral Payment Model for CAR-T Therapies," 2022.
